Coordinatore | TROPHOS SA
Organization address
address: PARC SCIENTIFIQUE LUMINY CASE 931 contact info |
Nazionalità Coordinatore | France [FR] |
Sito del progetto | http://www.mitotarget.eu |
Totale costo | 10˙332˙037 € |
EC contributo | 5˙999˙980 € |
Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
Code Call | FP7-HEALTH-2007-B |
Funding Scheme | CP-FP |
Anno di inizio | 2009 |
Periodo (anno-mese-giorno) | 2009-02-01 - 2012-03-31 |
# | ||||
---|---|---|---|---|
1 |
TROPHOS SA
Organization address
address: PARC SCIENTIFIQUE LUMINY CASE 931 contact info |
FR (MARSEILLE CEDEX 9) | coordinator | 1˙860˙680.00 |
2 |
THE UNIVERSITY OF SHEFFIELD
Organization address
address: FIRTH COURT WESTERN BANK contact info |
UK (SHEFFIELD) | participant | 694˙737.00 |
3 |
KING'S COLLEGE LONDON
Organization address
address: Strand contact info |
UK (LONDON) | participant | 691˙983.00 |
4 |
UNIVERSITE D'AIX MARSEILLE
Organization address
address: Boulevard Charles Livon 58 contact info |
FR (Marseille) | participant | 560˙192.00 |
5 |
JOHANN WOLFGANG GOETHE UNIVERSITAET FRANKFURT AM MAIN
Organization address
address: GRUNEBURGPLATZ 1 contact info |
DE (FRANKFURT AM MAIN) | participant | 416˙841.00 |
6 |
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Organization address
address: GESCHWISTER-SCHOLL-PLATZ contact info |
DE (TUEBINGEN) | participant | 391˙477.00 |
7 |
UNIVERSITAET ULM
Organization address
address: HELMHOLTZSTRASSE 16 contact info |
DE (ULM) | participant | 194˙239.00 |
8 |
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
Organization address
address: 3 Avenue Victoria contact info |
FR (PARIS) | participant | 187˙984.00 |
9 |
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Organization address
address: Chariteplatz 1 contact info |
DE (BERLIN) | participant | 174˙376.00 |
10 |
MEDIZINISCHE HOCHSCHULE HANNOVER
Organization address
address: Carl-Neuberg-Strasse 1 contact info |
DE (HANNOVER) | participant | 163˙455.00 |
11 |
Centre hospitalier universitaire de Limoges
Organization address
address: avenue Martin-Luther-King 2 contact info |
FR (Limoges) | participant | 144˙877.00 |
12 |
KATHOLIEKE UNIVERSITEIT LEUVEN
Organization address
address: Oude Markt 13 contact info |
BE (LEUVEN) | participant | 142˙031.00 |
13 |
HOSPICES CIVILS DE LYON
Organization address
address: 3 Quai des Celestins contact info |
FR (LYON) | participant | 98˙258.00 |
14 |
CHU DE NICE
Organization address
address: AVENUE VICTORIA 4 contact info |
FR (NICE) | participant | 84˙193.00 |
15 |
CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE
Organization address
address: AVENUE OSCAR LAMBRET 2 contact info |
FR (LILLE) | participant | 73˙201.00 |
16 |
CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER
Organization address
address: Avenue du Doyen Gaston Giraud 191 contact info |
FR (MONTPELLIER) | participant | 68˙381.00 |
17 |
MARTIN-LUTHER-UNIVERSITAET HALLE-WITTENBERG
Organization address
address: UNIVERSITAETSPLATZ 10 contact info |
DE (HALLE (Saale)) | participant | 53˙075.00 |
18 |
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Organization address
address: HEIDELBERGLAAN 100 contact info |
NL (UTRECHT) | participant | 0.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'Mitochondrial dysfunction is a major hallmark of various neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, Huntington’s diseases or Amyotrophic Lateral Sclerosis (ALS). However linking mitochondrial dysfunction to the pathogenesis of some of these diseases still needs to be elucidated. Furthermore, in pathologies where this link is already established, the question remains whether specific targets or mechanisms involved in mitochondrial dysfunction will be amenable to therapeutic intervention. MitoTarget is an ambitious project aimed at providing solid data to better understand and exploit the circumstantial evidence linking mitochondrial dysfunction with neuronal dysfunction culminating in neurodegenerative disease. A 36 months translational research program will bring together a unique partnership between basic scientists, a seasoned team of clinical investigators and a SME that has identified a first-in-class compound, TRO19622, that targets mitochondria and has powerful neuroprotective and neuroregenerative activities. In parallel, and orchestrated by the SME that is the coordinator of the project, MitoTarget will bring together a more comprehensive insight into the mechanisms leading to mitochondrial impairments and establish their clinical relevance in a severe orphan neurodegenerative disease, ALS. If successful, it is expected that from this proof of principle a new class of therapeutic agents targeting the underlying mitochondrial dysfunction in neurons or their supporting cells will emerge. Results of the project have the potential to create a new paradigm for the drug discovery for neurodegenerative diseases.'
An EU project is investigating how proper mitochondrial functioning is vital for warding off neurodegeneration and brain diseases such as Alzheimer's.
Development of a high sensitive and specific nanobiosensor based on surface enhanced vibrational spectroscopy dedicated to the in vitro proteins detection and disease diagnosis
Read More